Cesium carbonate → tert-butyl (3R)-3-[[5-(5-carbamoyl-1,3-benzothiazol-2-yl)-6-methoxy-2-(morpholin-4-yl)pyrimidin-4-yl]amino]piperidine-1-carboxylate

HRID 1507542Notes

Reaction equation

HRID 1507542 reaction equation
[S:1]1[C:5]2[CH:6]=[CH:7][C:8]([C:10]([NH2:12])=[O:11])=[CH:9][C:4]=2[N:3]=[CH:2]1.I[C:14]1[C:15]([NH:28][C@@H:29]2[CH2:34][CH2:33][CH2:32][N:31]([C:35]([O:37][C:38]([CH3:41])([CH3:40])[CH3:39])=[O:36])[CH2:30]2)=[N:16][C:17]([N:22]2[CH2:27][CH2:26][O:25][CH2:24][CH2:23]2)=[N:18][C:19]=1[O:20][CH3:21].C(=O)([O-])[O-].[Cs+].[Cs+]>CN(C=O)C.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1.[Cu](I)I>[C:10]([C:8]1[CH:7]=[CH:6][C:5]2[S:1][C:2]([C:14]3[C:15]([NH:28][C@@H:29]4[CH2:34][CH2:33][CH2:32][N:31]([C:35]([O:37][C:38]([CH3:41])([CH3:40])[CH3:39])=[O:36])[CH2:30]4)=[N:16][C:17]([N:22]4[CH2:23][CH2:24][O:25][CH2:26][CH2:27]4)=[N:18][C:19]=3[O:20][CH3:21])=[N:3][C:4]=2[CH:9]=1)(=[O:11])[NH2:12]

Participants

7

Procedure

Following the same procedure as in step 3 of Example 337 using 1,3-benzothiazole-5-carboxamide (60.6 mg, 0.34 mmol, 1.80 equiv), tert-butyl (3R)-3-[[5-iodo-6-methoxy-2-(morpholin-4-yl)pyrimidin-4-yl]amino]piperidine-1-carboxylate (100.0 mg, 0.19 mmol, 1.00 equiv), cesium carbonate (0.38 g, 6.00 equiv), Pd(PPh3)4 (39.3 mg, 0.034 mmol, 0.18 equiv) and copper iodide (6.5 mg, 0.034 mmol, 0.18 equiv) in DMF (5.0 mL). The crude product was purified by flash chromatography on a silica gel column eluting with ethyl acetate/petroleum ether (1:15-1:1) to provide the title compound as a white solid. MS m/z [M+H]+ (ESI): 570.

Workup

  1. customThe crude product was purified by flash chromatography on a silica gel column
  2. washeluting with ethyl acetate/petroleum ether (1:15-1:1)

Sources & evidence

ORD record
ord-ae5d7eb9456c4be396a35c2010267113
Source dataset
uspto-grants-2015_12
Patent number
US09221809B2

Reaction notes

Loading…